214 results
8-K
EX-99.1
LUMO
Lumos Pharma Inc
7 Nov 23
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD
4:08pm
that the primary purpose of this study was not to establish efficacy or demonstrate non-inferiority compared to daily GH treatment.
OraGrowtH212
424B5
LUMO
Lumos Pharma Inc
29 Aug 22
Prospectus supplement for primary offering
5:14pm
, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty … or report filed for the purpose of updating such description, including Exhibit 4.2 to our Annual Report.
You may request a copy of these filings
S-8
5dcb7kkvvvnzrkfb
27 Aug 21
Registration of securities for employees
12:00am
8-K
EX-99.2
f4s1w2nx10vc2 eleyd
23 Aug 21
Other Events
4:43pm
8-K
EX-99.1
yve5vcgyt os6u9a
23 Aug 21
Other Events
4:43pm
8-K
EX-99.1
upk785lzbl16y9etl73k
5 May 21
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
4:28pm